Clinical trial Recruiting at 1 site Observational Women only

Effects of Aromatase Inhibitors on Heart and Brain Health in Breast Cancer Survivors

Official title: Beyond Cardiotoxicity: Characterizing the Long-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment

Run by University of Toronto · NCT06776458 · Data updated 2026-11-12

This study looks at how taking aromatase inhibitors affects heart and brain health over time in post-menopausal women who have survived hormone receptor-positive breast cancer.

More Breast Cancer Females trials

Quick facts

Study typeObservational
SexWomen only
Enrollment112 (estimated)
SponsorUniversity of Toronto
Academic / other
Drugs / interventionsradiation
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedFebruary 1, 2025
Main results expectedSeptember 30, 2026
Study endsSeptember 30, 2026
Registry record updatedJanuary 15, 2025
Trial IDNCT06776458 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include post-menopausal women with hormone receptor-positive breast cancer who have received aromatase inhibitor therapy.

Probably not a fit

Patients who have previously undergone treatment with tamoxifen or those with other significant cardiovascular conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the long-term cardiovascular and brain health outcomes associated with aromatase inhibitor therapy in post-menopausal women diagnosed with hormone receptor-positive breast cancer. It will compare health indices related to cardiovascular disease in breast cancer survivors at 1, 5, and 10 years post-diagnosis to a control group. The primary focus is on assessing early risk indicators for cardiovascular disease, including aortic stiffness, to better understand the implications of prolonged aromatase inhibitor use.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the cardiovascular risks associated with aromatase inhibitors, potentially leading to improved management strategies for breast cancer survivors.

How similar studies have gone: While studies have indicated cardiovascular risks associated with aromatase inhibitors, this specific long-term observational approach is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Case group:

* Biologically female
* Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year
* If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.
* Diagnosis of stage I, II, or III breast cancer
* Hormone receptor positive breast cancer
* HER negative (ER+/PR+/HER-) breast cancer
* Breast cancer patients \~1 post-diagnosis who have received aromatase inhibitor therapy
* Breast cancer patients \~5 and \~10 years post-diagnosis who have received aromatase inhibitor therapy for at least 2 years
* Received surgery/radiation therapies

Control group:

* Biologically female
* Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year
* If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.

Exclusion Criteria:

* Previous treatment using tamoxifen endocrine therapy in a pre-or peri-menopausal setting
* Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)
* American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure \>200mmHg/100mmHg, a cancer diagnosis other than skin cancer)
* Unable to provide informed consent or communicate in English
* Mobility limitations to exercise testing (i.e., wheelchair, walker use, limp impeding walking)
* Extreme claustrophobia

Where it's running

  • University of Toronto
    Toronto, Ontario, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.